



International Journal of Medical Research & Health Sciences

www.ijmrhs.com Volume 2 Issue 1 Jan-Mar 2013 Coden: IJMRHS Copyright ©2013 ISSN: 2319-5886

Received: 5th Dec 2012

Revised: 25th Dec 2012

Accepted: 29th Dec 2012

Original research article

A STUDY OF ANTI-HYPERLIPIDEMIA, HYPOLIPEDIMIC AND ANTI-ATHEROGENIC ACTIVITY OF FRUIT OF EMBLICA OFFICINALIS (AMLA) IN HIGH FAT FED ALBINO RATS

*Jeevangi Santoshkumar¹, Manjunath S², Sakhare Pranavkumar M³

¹Associate Professor, ³Post Graduate Student Department of Pharmacology, M.R Medical College, Gulbarga, Karnataka, India.

²Professor, Department of Pharmacology, S. Nijalingappa Medical College, Bagalkot, Karnataka, India.

*Corresponding author email: drsantoshkumar.2007@rediffmail.com

ABSTRACT

Background: Emblica Officinalis (Amla), belonging to the genus, Phyllanthus emblica is widely used for medicinal purpose. Its fruits have been used traditionally as a hypolipidemic. **Objectives:** The present study was aimed to evaluate hypolipidemic and anti-atherogenic activity of fruit of Emblica officinalis in high fat fed albino rats. **Materials and Methods:** For study of anti-hyperlipidemic, hypolipidemic, and anti-atherogenic activity. 5 groups of 6 animals in each received normal saline, E. Officinalis powder, high fat diet, High fat diet plus E. Officinalis powder both and Atorvastatin respectively for 8 weeks. Hyperlipidemia was induced by feeding animals with high fat diet per orally, consisting of coconut oil and vanaspati ghee, daily ad libitum. At the end of the study, blood samples of the animals were sent for the estimation of the lipid profile and effects of test drug studied by comparing levels of Total Cholesterol, Triglycerides, HDL, LDL, and Atherogenic index. The statistical significance between groups was analysed by using one way ANOVA, followed by Dunnet's multiple comparison test. **Results:** Fruit of Amla showed significant anti-hyperlipidemic, hypolipidemic, and anti-atherogenic effect. All these effects may contribute to its anti-atherogenic activity. **Conclusion:** Present study revealed the anti-hyperlipidemic, hypolipidemic, and anti-atherogenic effect of Amla fruit powder and can be safely used in the treatment of mild to moderate cases of hyperlipidemia considering its easy availability, cost effectiveness, and other beneficial effects.

Key Words: Emblica Officinalis, Hypolipidemic, Anti-Atherogenic, Atorvastatin, Atherogenic Index.

INTRODUCTION

Hyperlipidemia is one of the major culprits for various cardiovascular and central nervous system

disorders. Both genetic disorders and diet enriched with saturated fats and cholesterol,

contribute to the elevated lipid levels in our population as well as in many other developed countries around the world¹.

Atherosclerosis is an age related disease. It is widely prevalent in industrialized countries, affecting primarily the intima of large and medium sized arteries and is characterized by fibrous-fatty plaques or atheroma². The cause of atherosclerosis is not known, although several risk factors have been involved in the pathogenesis of atherosclerosis. Current experimental and epidemiological evidence suggests a strong relationship between atherosclerosis and elevated levels of plasma lipids. Recent work also incriminated folic acid deficiency leading to elevated plasma levels of homocysteine and chronic infection with chlamydia pneumonia in the pathogenesis³. Atherosclerosis, which was earlier thought to be always associated with hypercholesterolemia, has now been proved as an inflammatory disease⁴.

Over the last few years the changes in the lifestyle, particularly the westernization of the diet and a relatively sedentary lifestyle have led to an increased frequency of lifestyle related disorders such as hyperlipidemia, diabetes mellitus, and atherosclerosis⁵. The principle metabolic causes of atherosclerosis include hyperlipidemia, hypertension, obesity, insulin resistance, and diabetes mellitus⁶. Risk factors for the above are the following, Smoking, hypertension, serum cholesterol, genetic factors, physical activity, hormones, alcohol, thyroid disease, renal disease, and liver disease⁷.

The current National Cholesterol Education Program (NCEP) for the management of patients with lipid disorder is of 2 types. One is population based approach, which is intended to lower blood cholesterol by dietary recommendations such as reduced total calories from fats to less than 305kCal and from saturated fats to less than 10%, consumption of less than 300mg of cholesterol per day and maintenance of desirable body weight.

The second is a patient based approach described in the report 2001 report of NCEP.

Adult treatment panel-III (ATP-III) which continues to focus on lowering LDL-C levels as the primary goal of the therapy⁸. The ATP-III report recognizes four classes of drugs that may be used to achieve lipid goals. These include HMG-CoA reductase inhibitors (Statins), Bile Acid sequestrants, Niacin, and Fibric acid derivatives⁹.

The history of natural products is as old as mankind. The importance of traditional systems of medicine and of certain traditional medical practices has now been recognized all over the world. Today, it is required to have an intelligent and pragmatic approach to evaluate selective drugs of herbal origin. Therefore, it should really matter for Pharmacologists to obtain information from traditional healers, about their remedies and to extract the active principles for development into drugs¹⁰.

E. Officinalis or *Phyllanthus emblica* (Syn: Amla, Indian Gooseberry) is an evergreen tree which is highly prized in tropical Asia. The genus is natural to tropical Southeast Asia, particularly in Central and South India. It is commonly cultivated in gardens throughout India and grown commercially as a medicinal fruit¹¹. It is among the most important medicinal plants in the Ayurveda Materia Medica and widely used in Indian medicines for the treatment of various ailments¹².

Apart from traditional uses, there are several reports in the pharmacological actions of Amla based on modern scientific investigations, especially anti-inflammatory action¹³, antimicrobial action¹⁴, anti-oxidant action¹⁵, anti-carcinogenic action¹⁶, anti-ulcerogenic action¹⁷, anti-diabetic action¹⁸, analgesic action¹⁹, and hepato protective action²⁰.

The credit for initiating studies related to herbal extracts in our country goes to Sir Ram Nath Chopra and his team of dedicated workers, in Calcutta School of Tropical Medicine²¹.

Keeping in view of the above ideas, the present study has been undertaken to evaluate the effect of *E. officinalis* powder on the serum lipids level, in albino rats fed with high fat diet comparing with standard hypolipidemic drug Atorvastatin.

MATERIALS AND METHODS

The experimental protocol was approved by the Institutional Ethics Committee and Animal Ethics Committee of M.R Medical College, Gulbarga. The study was carried out in 30 healthy albino rats of Wister strain (*Rattus norvegicus*) weighing 150-200g either sex. Animals were maintained on a standard animal diet consisting of Bengal gram, Wheat, Maize, and Carrot in sufficient quantity for the entire period (8 weeks) of the study and Water *ad libitum*.

Drugs used in the study:

1. **Emblica officinalis:** The powder obtained from Phytopharma Ayurvedic firm from Kolhapur, Maharashtra. The dose in humans is 6g/day, which is equivalent to 540mg/kg in rats²².
2. **Atorvastatin:** Atorvastatin powder was obtained from Biocon Pharmaceuticals, Bengaluru. Human dosages 80mg, which is 7.2mg/kg in rats²².
3. **High Fat Diet:** Mixture of Coconut Oil (from Marico Industries Ltd., Mumbai) and Vanaspati Ghee procured from Ruchi Industries, Mumbai.
4. **Vehicle:** Gum Acacia: 4%, 2ml/kg procured from Nice chemicals, Kochi

Preparation of High Fat Diet for inducing Hyperlipidemia:

Edible Coconut oil and Vanaspati ghee mixed together in the ratio of 2:3 v/v as per the method of Shymala MP et al²³, at a dose of 10ml/kg body weight, was fed to the animals per oral daily in addition to a normal diet for 8 weeks.

Study Design

For the study, the animals were weighed, recorded, numbered, and randomly divided into 5

groups of 6 animals each for a period of 8 weeks according to CPCSEA (Committee for the purpose of control and supervision of experiments on animals) for laboratory animal facilities^{24, 25}.

Grouping and Treatment Schedules

Group 1: Normal Saline

Group 2: *E. officinalis* powder 540mg/kg/day along with normal diet.

Group 3: High Fat Diet (10ml/kg/day)

Group 4: High fat diet (10ml/kg/day) + *E. officinalis* powder (540mg/kg/day)

Group 5: High fat diet (10ml/kg/day) + Atorvastatin (7.2mg/kg/day)

All the animals used for the study were kept under observation for daily food intake. The drugs were administered to the animals for 8 weeks by an intra-gastric feeding tube. At the end of 8th week, all the group of animals was kept for overnight fasting, After overnight fasting 2ml of blood was collected from the orbital sinus with the help of a capillary tube by pressing the thumb behind the angle of the jaw resulting in the engorgement of retro-orbital plexus²⁶. The blood was centrifuged; serum was collected and used for assessing the various biochemical parameters of the lipid profile.

Biochemical Estimation

Biochemical parameters were estimated in the Biochemistry Laboratory of Basaveshwara Teaching and General Hospital, attached to M. R. Medical College, Gulbarga.

The following parameters of Lipid Profile were measured:

1. Total Serum Cholesterol- It was estimated by using Erba Kit²⁷ manufactured by Transasia Bio-Medicals Ltd.
2. Serum Triglyceride- It was estimated by using a kit manufactured by AGAPPE Diagnostics²⁸.
3. High Density Lipoprotein Cholesterol (HDL) - It was estimated by using Erba Kit²⁷ manufactured by Transasia Bio-Medicals Ltd.

4. Low Density Lipoprotein Cholesterol (LDL) - It was estimated by using Erba Kit ²⁷ manufactured by Transasia Bio-Medicals Ltd.

Atherogenic Index:

The Atherogenic index was calculated by using the formula ²⁹.

$$\text{Atherogenic Index} = \frac{\text{Total Cholesterol} - \text{HDL}}{\text{HDL}}$$

Statistical Analysis

The statistical significance between groups was analysed by using one way ANOVA, followed by Dunnet’s multiple comparison test. The significance was expressed by ‘p’ values, as mentioned in the table.

RESULTS

The results obtained are summarised in table 1. The values obtained were expressed in specific units of those parameters as mentioned in the table. The results of estimation were reported as

Mean ± SEM (standard error of mean) of 6 animals at a time from each group. It was seen that, there was a significant increase in all the lipid parameters (p < 0.01), except HDL, following administration of high fat diet. It was also seen that concomitant administration of the Amla powder at a dose of 540mg/kg body weight along with high fat diet in the study animals, showed a significant decrease in all the lipid parameters (p <0.01) i.e. hypolipidemic and antihyperlipidemic activity with a significant rise in the value of serum HDL (p < 0.01). Standard drug Atorvastatin at a dose of 7.2mg/kg administered along with a high fat diet, showed a significant decrease (p < 0.01) in all the lipid parameters, while there was a significant increase in serum HDL. The hypolipidemic activity of the test drug was found to be slightly less efficacious than that of the standard drug, in comparison to the control. (Figure 1)

Table: 1. Effects of fruit powder of E. officinalis on serum lipids at the end of 8th week of study.

Group	Total Cholesterol (mg/dl)	Triglyceride (mg/dl)	HDL(mg/dl)	LDL(mg/dl)	Atherogenic Index ratio
Group 1	88.7 ± 5.5	66.76 ± 3.02	26.35 ± 1.68	48.98 ± 2.96	2.42 ± 0.20
Group 2	80.4 ± 5.75*	57.5 ± 1.39*	35.5 ± 1.28*	32.70 ± 1.21*	1.27 ± 0.04*
Group 3	267.0 ± 7.56*	218.48 ± 9.19*	16.0 ± 0.90*	207.25 ± 7.81*	15.92 ± 1.06*
Group 4	99.1 ± 1.47†	83.6 ± 1.88†	25.7 ± 1.5†	50.13 ± 3.92†	2.91 ± 0.23†
Group 5	77.5 ± 4.7†	57.03 ± 3.26†	37.05 ± 1.4†	29.0 ± 4.0†	1.11 ± 0.16†
F	330.01	219.80	44.28	312.84	149.97
Df	25, 4	25, 4	25, 4	25, 4	25, 4
P	<0.01	<0.01	<0.01	<0.01	<0.01

* : p < 0.01, when compared with the normal control group;
 † : p < 0.01, when compared with the hyperlipidemic control group.
 (One way ANOVA followed by Dunnet’s multiple comparison test)
 Data presented as Mean ± SEM

www.IndianJournals.com
Members Copy, Not for Commercial Sale
Downloaded from IP: 144.222.82.133 on dated 17-Sep-2024




Figure-1: Graph showing mean serum lipid parameters in 5 groups at the end of 8th week.

DISCUSSION

Hyperlipidemia was induced by administering a high fat diet to the albino rats. Shyamala MP et al²³ stated that hyperlipidemia is a result of an oxidative abuse due to free radicals, formed by the interaction of high fat diet. They further stated that, an enhancement in the concentration of serum cholesterol and triglycerides of hyperlipidemia rats maybe result of lipid peroxidation evoked by high fat diet³⁰. In the present study, Atorvastatin was used as a standard drug³¹.

E. Officinalis powder, administered in hyperlipidemia rats can elicit a profound influence on the lipid metabolism. An enhancement in the concentration of total serum cholesterol, serum triglycerides, serum LDL, Atherogenic index of hyperlipidemia rats was observed, which was probably due to lipid peroxidation evoked by high fat diet. Lipid peroxidation is a free radical mediated process which has been implicated in a variety of disease states.³² HDL concentration and HDL ratio would be useful in diseases like diabetes mellitus and coronary heart disease, because of their inverse relationship.³³ High LDL levels are usually associated with atherosclerosis³⁴

Hyper triglyceridemia is also associated with metabolic consequences of hyper coagulability, hyperinsulinemia, insulin resistance, and glucose resistance, and is one of the risk factors in the coronary heart disease³⁵.

Hypolipidemic efficacy of *E. officinalis* powder is revealed by attainment of values below normal in the lipid profile of group 2 rats. The anti - hyperlipidemia activity of *E. officinalis* powder is established by the attainment of near normal values in lipid parameters of group 4 rats. The hypolipidemic effect of *E. officinalis* may have a protective mechanism against the development of atherosclerosis. Anti lipoperoxidative property of *E.officinalis* powder, maybe due to its rich flavonoids and poly phenol contents. It is well known that flavonoids and poly phenols are natural anti-oxidants^{36,37}.

Recent epidemiological studies have revealed that the intake of flavonoids is inversely associated with the risk of coronary heart disease. *E. Officinalis* powder, rich in flavonoids and poly phenols may also be contributing towards its hypolipidemic effect, due to its ability to combat oxidative stress by quenching free radicals

generated in the body as a result of high fat diet. *E. officinalis* powder may also act by triggering the secretion of anti-oxidant enzymes: Superoxide dismutase, Catalase, and Glutathione peroxidase in an enhanced level, which in turn stopped the oxidative damage due to hyperlipidemia. Dhuley JN et al³⁸ and Shyamala MP et al²³ have documented a similar observation with *Cinnamomum verum* bark and *Amoma subulatum* seeds and *Syzygium aromaticum* respectively in rats fed with high fat diet.

The present study which was done to evaluate the effect of *E. officinalis* on serum lipids and atherogenesis in albino rats is in agreement with other studies^{39, 40}. As compared to the other studies, in the present study *E. officinalis* powder was used, which is easily available and inexpensive. In previous studies, *E. officinalis* aqueous and ethanolic extract has been used. The present study was carried out for a longer duration of time, i.e. 8 weeks as compared to the previous studies which were done for 4 week duration.

As atherosclerosis is closely associated with hyperlipidemia, it is beneficial to compare it with a standard drug such as Atorvastatin. Such a comparative study was not done before. Amla has shown to possess significant hypolipidemic and anti-atherogenic activity slightly lesser as compared to Atorvastatin. But if we compare Amla with Atorvastatin in terms of adverse effect profile, Atorvastatin can cause severe adverse effects like rhabdomyolysis to mention one of them⁴¹.

CONCLUSION

Amla can be safely used in the treatment of mild to moderate cases of hyperlipidemia considering its easy availability, cost effectiveness, and other beneficial effects.

Not many studies have been undertaken to fully evaluate the molecular and biochemical basis of hypolipidemic action of Amla and further clinical

studies are required to find out the hypolipidemic activity and molecular mechanism.

ACKNOWLEDGEMENT

The Authors wish to extend their gratitude to Dr Prashant Dass (Post Graduate/Tutor, Department of Pharmacology, MR Medical College, Gulbarga) for helping in the preparation of this manuscript.

REFERENCES

1. Norma ED. Atherosclerosis-An Inflammatory Process. *J Insur Med* 2005; 37: 72-75.
2. Nobukoni Y, Higashikawa F, Miyagawa K, et al. Hyperlipidemia: Complex Pathophysiology caused by multiple genetic and environmental forces in considering the approaches to preventive medicine. *Nippon Eiseigaku Zasshi* 2005; 60 (4): 426-41.
3. Shoulder CC, Jones EL, Naoumova RP. Genetics of familial combined hyperlipidemia risk of coronary heart disease. *Hum Mol Genet* Apr 2004; 1,13 Spec No.1: R 149-160, *Equb*; 5.
4. Daniel JR, Helen HH. Disorders of Lipoprotein metabolism: Harrison's Principles of Internal Medicine 18th Edition, McGraw Hill Medical Publisher Division 2012;2: 3145-61.
5. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent Clinical trials for the National Cholesterol Education Program: Adult Treatment Panel III Guidelines. *Circulation*. 2004; 110: 227-39.
6. Lloyd Jones DM, Hong Y, Labartha D, et al. Defining and setting National goals for cardiovascular health promotion and disease reduction. The American Heart Association's Strategic Impact goal through 2020 and beyond. *Circulation*. 2010; 121: 586-613.
7. Rybicki EP, Chikwamba R, Koch M, Rhodes JI, et al. Plant-made therapeutics: an emerging

- platform in South Africa. *Biotechnol Adv.* 2012; 30 (2): 449-59.
8. Nair R, Chanda SV. Antibacterial Activities of Some Medicinal Plants of the Western Region of India. *Turk J Biol.* 2007;31: 231-36.
 9. Sultan S, Ahmed S, Sharma S, Jahangir T. *E. officinalis* reverse thioacetamide induced oxidative stress and early promotional events of primary hepatocarcinogenesis. *J Pharma Pharmacol.* 2004; 56(12): 1573-79.
 10. Muthuraman A, Sood S, Singla SK. The antiinflammatory potential of phenolic compounds from *Emblica officinalis* L. in rat. *Inflammopharmacology.* 2011; 19 (6): 327-34.
 11. Prachi J and Shilpa S. Antimicrobial properties and phytochemical analysis of *Emblica officinalis*. *Asian J.Exp. Biol. Sci.* 2010;1(1):91-95.
 12. Poltanov EA, Shikov AN, Dorman HJ, Pozharitskaya ON, Makarov VG, Tikhonov VP, Hiltunen R. Chemical and antioxidant evaluation of Indian gooseberry (*Emblica officinalis* Gaertn., syn. *Phyllanthus emblica* L.) supplements. *Phytother Res.* 2009; 23 (9): 1309-15.
 13. Madhuri S, Pandey G, Verma KS. Antioxidant, Immunomodulatory and Anticancer activities of *Emblica Officinalis*: An overview. *IRJP.* 2011; 2 (8):38-42.
 14. Rajeshkumar NV, Therese M, Kuttan R. *Emblica officinalis* Fruits Afford Protection against Experimental Gastric Ulcers in Rats. *Therm Biol.* 2001;39 (5): 375-80.
 15. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (*Emblica officinalis* Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. *Int J Food Sci Nutr.* 2011; 62 (6): 609-16.
 16. Sadaf H, Mohd D, Mohd A, Kunal S, Praveen KV, Asad UK. Efficacy of *E. Officinalis* on the Cariogenic Properties of *Streptococcus mutans*: A Novel and Alternative Approach to Suppress Quorum-Sensing Mechanism. *PLoS ONE* 7 (7): e40319
 17. Anil UT, Sanjay JS, Manisha PS, and Nehal HG. Hepatoprotective effect of poly herbal formulation against various hepatotoxic agents in rats. *Pharmacognosy Res.* 2012; 4 (1): 50–56.
 18. Vaidya ADB. Reverse pharmacological correlates of Ayurvedic drug actions. *Indian J Pharmacol.* 2006: 38(5); 311-15.
 19. Ghosh MN. Toxicity studies. *Fundamental of Experimental Pharmacology* 4th Edition, Hilton and Company, Calcutta, 2008; 178.
 20. Shymala MP, Venukumar MR, Lata MS. Antioxidant potential of the *Syzygium aromaticum* (Gaertn) Linn (Clove) in rats fed with high fat diet. *Indian Journal of Pharmacology* 2003;35:99-103.
 21. CPCSEA Guidelines for laboratory animal facility. *Indian J Pharmacol, Special Article.* 2003;35, (4): 257-274.
 22. Pereira S, Tettamanti M. Ahimsa and alternatives -- the concept of the 4th R. *The CPCSEA in India.* *Altex* 2005, 22 (1): 3-6.
 23. Van HH, Baumans V, Brandt CJ, Boere HA, Hesp AP, van Lith HA, Schurink M, Beynen AC. Blood sampling from the retro-orbital plexus, the saphenous vein and the tail vein in rats: comparative effects on selected behavioural and blood variables. *Lab Anim.* 2001; 35 (2): 131-9.
 24. Sarika SS and Aarti GJ. Effects of methanolic extract of *Cuminum cyminum* on total serum cholesterol in ovariectomized rats. *Indian J Pharmacol.* 2009; 41 (2): 92–93.
 25. Urmila CK, Shraddha NS, Sandesh PJ. Evaluation of hypoglycemic activity of *Cassia nodosa* leaves in normal and streptozotocin-induced diabetic rats. *Int J Green Pharm* 2012; 6: 9-13.
 26. Milada Dobiášová. Atherogenic Index of Plasma [Log (Triglycerides/HDL-Cholesterol)]: Theoretical and Practical

Implications. *Clinical Chemistry* July 2004;50(7): 1113-17.

27. Park HR, Park M, Choi J, Park KY, Chung HY, Lee J. A high-fat diet impairs neurogenesis: involvement of lipid peroxidation and brain-derived neurotrophic factor. *Neurosci Lett*. 2010; 4 (3): 235-39.
28. Harikrishnan S, Rajeev E, Tharakan JA, Titus T, Ajit Kumar VK, Sivasankaran S, Krishnamoorthy KM, Nair K. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol. *Indian Heart J*. 2008;60(3): 215-22.
29. Etsuo N, Yasukazu Y, Yoshiro S , Noriko N. lipid peroxidation: Mechanisms, inhibition and biological effects. *Biochemical and Biophysical Research Communications*. 2005;338: 668-76.
30. Boizel R, Laporte F, Benhamou YP, Foulon T, Lardy B, Halimi S. Ratio of Triglycerides to HDL Cholesterol as an Indicator of LDL Particle Size in Patients With Type 2 Diabetes and Normal HDL Cholesterol Levels. *Diabetes Care*. 2000;23(11): 1679-85.
31. Montalcini T, Gorgone G, Federico D, Emanuele V, Sesti G, Ceravolo R, Pujia A, Perticone F. Association of LDL cholesterol with carotid atherosclerosis in menopausal women affected by the metabolic syndrome. *Nutrition, Metabolism & Cardiovascular Diseases*. 2005; 15: 368-72.
32. Byron JH, Dennis LS, Vijay N. A truly deadly quartet: obesity, hypertension, hypertriglyceridemia, and hyperinsulinemia. *Cleveland Clinic Journal of Medicine*. 2002;69(12): 989-89.
33. Vinson JA, Liang X, Proch J, Hontz BA, Dancel J, Sandone N. Polyphenol antioxidants in citrus juices: in vitro and in vivo studies relevant to heart disease. *Adv Exp Med Biol*. 2002;505:113-22.
34. Pietta GP. Flavonoids as Antioxidants. *J. Nat. Prod.*, 2000, 63 (7): 1035-42.
35. Dhuley JN. Anti oxidant effect of cinnamon (*Cinnamomum verum*) bark and greater cardamom (*Amomum subula-tum*) seeds in rats fed with high fat diet. *Indian J Exp Boil* 1999; 37: 238-42.
36. Mishra M, Pathak UN, Khan AB. E.officinalis Gaertn and Serum Choesterol level in experimental rabbits. *Br J Exp Pathol*. 1981; 62 (5): 526-28.
37. Gulati RK, Aggarwal S, Aggarwal SS. Hepatoprotective studies on *Phyllanthus emblica* Linn and quercetin. *Indian Journal of Experimental Biology*. 1995; 33: 261-68.
38. O'Sullivan S. Statins: A review of benefits and risks. *TSMJ*. 2007; 8: 52-56.
39. Thomas P B. Drug therapy for hypercholesterolemia and dyslipidemia. In: Laurence Burton, Bruce Chabner, Bjorn Knollman. *Goodman & Gilman's The Pharmacological Basis of Therapeutics*. 12th Edition. McGraw Hill, New York 2011; 877-908.
40. Harshmohan. *The Blood Vessels and Lymphatics: The Textbook of Pathology*, 4th Edition. Jaypee Brothers Medical Publisher (P) Ltd, Mumbai 2000; 252-54.
41. Satoskar RS, Bhandarkar SD, Rege NN. Appetite stimulants, Digestants, Anti flatulents, Appetite suppressants and Hypolipidemic agents. *Pharmacology and Pharmacotherapeutics*. 22nd Edition. Popular Prakashan Pvt Ltd, Mumbai 2011; 571-86.